Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan H Enas

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|September 10, 2009
Randomization by minimization for unbalanced treatment allocationBaoguang Han, Nathan H Enas, Damian McEntegart
British Journal of Clinical Pharmacology|May 3, 2016
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancerChiara Zecchin, Ivelina Gueorguieva, Nathan H Enas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Randomized phase II studies and their ethicsRaymond P Abratt, William H H Reece, Nathan H Enas, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|September 10, 2009
Randomization by minimization for unbalanced treatment allocationBaoguang Han, Nathan H Enas, Damian McEntegart
British Journal of Clinical Pharmacology|May 3, 2016
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancerChiara Zecchin, Ivelina Gueorguieva, Nathan H Enas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Randomized phase II studies and their ethicsRaymond P Abratt, William H H Reece, Nathan H Enas, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Pageof 1